首页> 美国政府科技报告 >Resuming Production of the Anthrax Vaccine as Quickly as Possible: Analysis of Alternative Business Arrangements, Volume 1: Main Report
【24h】

Resuming Production of the Anthrax Vaccine as Quickly as Possible: Analysis of Alternative Business Arrangements, Volume 1: Main Report

机译:尽快恢复生产炭疽疫苗:替代性商业安排分析,第1卷:主要报告

获取原文

摘要

A series of technical problems has delayed FDA approval for BioPort Corporation to deliver anthrax vaccine adsorbed (AVA) to the DoD. BioPort is preparing for a new FDA review, and the DoD is providing both financial relief and technical assistance to augment BioPort's efforts. Under this strategy, the earliest BioPort could gain FDA approval and resume AVA delivery is late May 2001. A more realistic expectation is delivery in the first half of 2002. IDA and the RAND Corporation studied the advantages and disadvantages of the DoD purchasing BioPort's Lansing, Michigan, AVA-production facility and converting it to a government-owned, contractor-operated (GOCO) operation. In one scenario, the DoD would select a new company to run the facility; in another, the DoD would have BioPort run the facility. We found that neither Option would result in vaccine being delivered faster than under the current strategy. Under the first GOCO scenario, the earliest AVA could be delivered would be 2003 (more probably late 2004). Under the second scenario, the earliest delivery date would be August 2001 (more probably late 2002). This report is the first of two volumes.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号